NeuroBo Pharmaceuticals (NRBO) shares were up nearly 8% in recent trading Wednesday after the company reported its Q2 results.
The company reported Q2 net loss of $1.85 per diluted share, widening from a loss of $0.15 a year earlier.
Three analysts surveyed by Capital IQ expected a loss of $1.12
The company did not report revenue for the quarter ended June 30.
NeuroBo Pharmaceuticals said it had $27.9 million in cash as of June 30 and expects its cash position to fund the company's operations into Q2 2025.
Price: 4.01, Change: +0.29, Percent Change: +7.80